Effective March 5, 2018, PathGroup has switched Herpes Simplex Virus 1 and 2 (HSV 1 & 2) detection from a laboratory developed Polymerase Chain Reaction (PCR) methodology to the FDA-approved Aptima HSV 1 & 2 Assay.
For more information, CLICK HERE
Latest Posts
TEST UPDATE: Influenza Type A/B, Molecular & Respiratory Virus Panel, Molecular
PathGroup now offers molecular-based testing for the most common pathogens associated with respiratory tract infections. These tests are intended for the simultaneous detection and identification of multiple viral nucleic acids in individuals suspected of respiratory tract infection.
For more information, CLICK HERE
TEST UPDATE: Mycoplasma genitalium
Effective today, February 12, 2018, PathGroup offers testing for Mycoplasma genitalium, intended for use as an aid in the diagnosis of M. genitalium urogenital infections in male and female patients.
For more information, CLICK HERE
TEST UPDATE: Human Immunodeficiency Virus 1 (HIV-1) Viral Load, by Quantitative PCR (with or without Reflex to HIV-1 Genotype)
Effective today, January 15, 2018, PathGroup will perform testing for Human Immunodeficiency Virus 1 (HIV-1) Viral Load via quantitative Real-Time PCR.
for more information, CLICK HERE
TEST UPDATE- White Blood Cell Count (WBC)
Effective December 11, 2017, PathGroup Labs will adjust the reference range for White Blood Cell Count (Test Code: WBC) for patients >12 years old.
For more information, CLICK HERE
TEST UPDATE – Glucose
Effective December 1, 2017, PathGroup Labs will adjust the glucose reference range for GLUCOSE (Test Code: GLU) to conform to the recommendations of the American Diabetes Association for the classification of prediabetes.
For more information, CLICK HERE
UPDATE: Non-Covered ICD-10 Codes
On November 1, 2017, a PathConnect software update will take place that will further restrict entry of any non-covered ICD-10 diagnosis codes for Medicare patients.
For more information, CLICK HERE
UPDATE: 2018 ICD-10 Updates: Z36 and Z3A
As a reminder, effective October 1, 2017, the 2018 ICD-10-CM updates are in effect (October 1, 2017 through September 30, 2018). Providers should be coding to the highest level of specificity per the 2018 ICD-10-CM updates. If an ICD code is entered that has been updated and/or now requires more specificity, suggestions for a more specific code will be displayed in PathConnect at the time of ordering as shown below.
For more information, CLICK HERE
New Prior Authorization Requirement for UnitedHealthcare
As a valued PathGroup partner, we wanted to inform you that starting November 1, 2017, notification/prior authorization will be required for certain genetic and molecular lab tests for certain UnitedHealthcare Commercial benefit plans. Ordering providers will now need to complete the prior authorization process online at the UnitedHealthcare Link Portal or over the phone.
PathGroup will be unable to complete the notification/prior authorization process for our healthcare providers. This new requirement impacts not only PathGroup, but all laboratories offering genetic and molecular based tests.
For more information,CLICK HERE
TEST UPDATE: Cystic Fibrosis Carrier Screening New Test Offering
Effective today, October 17, 2017, PathGroup offers a new test for Cystic Fibrosis (CF) Carrier Screening. In our effort to provide the most innovative and clinically applicable tests available, this new test includes 175 clinically relevant CFTR mutations, which improves the CFTR mutation detection rate across all ethnicities, particularly African Americans and Hispanic Americans. Professional medical organizations, including ACOG, recommend CF carrier screening be offered to all patients.1
For More Information, CLICK HERE